脯氨酸羟化酶3在乳腺癌中的表达及其对乳腺癌细胞恶性表型的影响

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (981 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression and function of the Egl nine homolog 3 (EGLN3) in breast cancer. Methods The expression of EGLN3 in 1085 cases of breast cancer tissues and 291 cases of normal tissues from the TCGA and GTEx databases was analyzed by using GEPIA website. A total of 52 cases of breast cancer tissues and adjacent tissues were collected in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from January 2010 to December 2017. The EGLN3 mRNA expression in breast cancer tissues was detected by real-time PCR. EGLN3 protein expression in normal breast epithelial cell (MCF-10A) and 11 cell lines of breast cancer (ZR-75-1, SK-BR-3, MDA-MB-453, BT474, MCF-7, T47D, MDA-MB-231, CAL-51, HS578T, MDA-MB-468, HCC1937) were detected by Western blot. The effect of transfection siRNA knockdown EGLN3 on proliferation, clonal formation, invasion and migration of breast cancer cells were detected by xCELLigence RTCA MP system, clonal formation assay and Transwell assay, respectively. Results The expression of EGLN3 mRNA in breast cancer tissues was higher than that in normal tissues， and the difference was statistically significant (P < 0.05). The expression of EGLN3 mRNA in breast cancer tissues was higher than that in adjacent tissues, and the difference was highly statistically significant (P < 0.01). EGLN3 protein was highly expressed in breast cancer cells MDA-MB-231, CAL-51, MDA-MB-468, and HCC1937, but not in normal breast epithelial cells and other breast cancer cells. After transfection with siRNA knockdown EGLN3, the proliferation, clonal formation, invasion and migration of breast cancer cells were decreased. Conclusion EGLN3 expression may be related to the occurrence and development of breast cancer, and down-regulation of EGLN3 can inhibit the malignant phenotype of breast cancer cells, but its mechanism needs further study.

Key words： Egl nine homolog 3 Breast cancer Proliferation Invasion Migration

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yang1 ZHAO Zitong2 SONG Yongmei2 ZHANG Bailin1

Cite this article:

WANG Yang1 ZHAO Zitong2 SONG Yongmei2 ZHANG Bailin1. Expression of Egl nine homolog 3 in breast cancer and its effect on malignant phenotype of breast cancer cells[J]. 中国医药导报, 2021, 18(28): 8-12,34.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I28/8

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Bertucci F，Ng CKY，Patsouris A，et al. Genomic characterization of metastatic breast cancers [J]. Nature，2019， 569（7757）：560-564.
[3] Xu Y，Gao Q，Xue Y，et al. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner [J]. J Biol Chem，2019，294（25）：9949-9958.
[4] Xue J，Li X，Jiao S，et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity [J]. Gastroenterology，2010，138（2）：606-615.
[5] Place TL，Fitzgerald MP，Venkataraman S，et al. Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells [J]. PLoS One，2011，6（1）：e14617.
[6] Hatzimichael E，Dasoula A，Shah R，et al. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia [J]. Eur J Haematol，2010， 84（1）：47-51.
[7] Dopeso H，Jiao HK，Cuesta AM，et al. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα [J]. Cancer Res，2018，78（7）：1805-1819.
[8] D’Angelo G，Duplan E，Boyer N，et al. Hypoxia up-regulates prolyl hydroxylase activity：a feedback mechanism that limits HIF-1 responses during reoxygenation [J]. J Biol Chem，2003，278（40）：38183-38187.
[9] Semenza GL. Oxygen sensing，homeostasis，and disease [J]. N Engl J Med，2011，365（6）：537-547.
[10] Morfoisse F，Kuchnio A，Frainay C，et al. Hypoxia induces VEGF-C expression in meta-static tumor cells via a HIF-1α-independent translation-mediated mechanism [J]. Cell Rep，2014，6（1）：155-167.
[11] Luo W，Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells [J]. Oncotarget，2011，2（7）：551-556.
[12] Zhang S，Zhou X，Wang B，et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma [J]. Oral Oncol，2014，50（9）：809-817.
[13] Appelhoff RJ，Tian YM，Raval RR，et al. Differential function of the prolyl hydroxylases PHD1，PHD2，and PHD3 in the regulation of hypoxia-inducible factor [J]. J Biol Chem，2004，279（37）：38458-38465.
[14] Bruick RK，McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF [J]. Science，2001，294（5545）：1337-1340.
[15] Luo W，Lin B，Wang Y，et al. PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility [J]. Mol Biol Cell，2014，25（18）：2788-2796.
[16] Garvalov BK，Foss F，Henze AT，et al. PHD3 regulates EGFR internalization and signal-ling in tumours [J]. Nat Commun，2014，5：5577.
[17] Metzen E，Berchner-Pfannschmidt U，Stengel P，et al. Intracellular localisation of human HIF-1 alpha hydroxylases：implications for oxygen sensing [J]. J Cell Sci，2003，116（Pt 7）：1319-1326.
[18] Jaakkola PM，Rantanen K. The regulation，localization，and functions of oxygen-sensing prolyl hydroxylase PHD3 [J]. Biol Chem，2013，394（4）：449-457.
[19] Egners A，Rezaei M，Kuzmanov A，et al. PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling [J]. Cancers（Basel），2018，10（12）：496.
[20] Henze AT，Garvalov BK，Seidel S，et al. Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR [J]. Nat Commun，2014，5：5582.
[21] Tang LR，Wu JX，Cai SL，et al. Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α [J]. Onco Targets Ther，2018，11：8507-8515.
[22] Jiang L，Liu QL，Liang QL，et al. Association of PHD3 and HIF2α gene expression with clinicopathological characteristics in human hepatocellular carcinoma [J]. Oncol Lett，2018，15（1）：545-551.
[23] H?觟gel H，Rantanen K，Jokilehto T，et al. Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells [J]. PLoS One，2011，6（11）：e27112.
[24] Chiba N，Sunamura M，Nakagawa M，et al. Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer [J]. Am J Cancer Res，2020，10（8）：2570-2581.
[25] Subik K，Lee JF，Baxter L，et al. The Expression Patterns of ER，PR，HER2，CK5/6，EGFR，Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines [J]. Breast Cancer（Auckl），2010，4：35-41.